Weight Loss: EnteroMedics Shares Tank After Device "Fails" Study

Mon, 02/11/2013 - 2:42pm
Mass Device

Weight loss devices maker EnteroMedics loses half of its Wall Street value after its VBloc vagal blocking therapy system fails to meet endpoints in a pivotal trial.

EnteroMedics' Maestro VBloc system

Wall Street fled in droves after weight-loss devices maker EnteroMedics (NSDQ:ETRM) announced that its Maestro vagal blocking system failed to meet endpoints in a pivotal study, but the mass exodus isn't discouraging the company from moving forward with a bid for FDA approval.

Treatment with Maestro therapy didn't hit targets in the ReCharge study, but rates of excess weight loss combined with the demonstrated safety profile of the neurostimulation implant may be enough to get the device through the premarket approval process, the company reported.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.